Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
May 20, 2020
- Astellas Confident of Hitting 3-Year Biz Goals on Xtandi, Full Backing of New Products
May 20, 2020
- Stella Pharma Launches New Cancer Radiation Therapy Steboronine
May 20, 2020
- Sawai, Nichi-Iko Hint at Delay in Edirol Generic Debut
May 20, 2020
- Astellas Eases Work-from-Home Policy in 39 Prefectures after Partial COVID-19 Emergency Lift
May 20, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- Mitsubishi Tanabe, Fuso to Copromote HIF-PH Inhibitor
May 19, 2020
- Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Enhertu Gets FDA’s Breakthrough Therapy Status for NSCLC
May 19, 2020
- Japan Ethical Drug Sales Down 2.9% in March: Crecon
May 18, 2020
- 7 Japan Major Drug Makers See Limited Impact from COVID-19: FY2019 Earnings
May 18, 2020
- Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
- Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
- Takeda’s Adcetris Gets EU OK for 1st-Line sALCL Treatment in Combo with Chemo
May 18, 2020
- Chugai Licenses Antibody Engineering Technologies to Lilly in COVID-19 Pact
May 18, 2020
- JT Files Riona for Iron Deficiency Anemia in Japan
May 18, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Ono Files Opdivo for 1st-Line Treatment for Unresectable Advanced/Recurrent Gastric Cancer
May 15, 2020
- Sumitomo Dainippon to Upscale Digital Info Provisioning, Face-to-Face Approach also Important: President
May 15, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…